|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Halbrook CJ and Lyssiotis CA: Employing
metabolism to improve the diagnosis and treatment of pancreatic
cancer. Cancer Cell. 31:5–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao G, Zhang Y, Zhao Z, Cai H, Zhao X,
Yang T, Chen W, Yao C, Wang Z, Wang Z, et al: MiR-153 reduces stem
cell-like phenotype and tumor growth of lung adenocarcinoma by
targeting Jagged1. Stem Cell Res Ther. 11:1702020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen
W, Chen H, Dong C, Yang R, Liu S, et al: Mifepristone suppresses
basal triple-negative breast cancer stem cells by down-regulating
KLF5 expression. Theranostics. 6:533–544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang W, Shen Y, Wei J and Liu F:
MicroRNA-153/Nrf-2/GPx1 pathway regulates radiosensitivity and
stemness of glioma stem cells via reactive oxygen species.
Oncotarget. 6:22006–22027. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun D, Mu Y and Piao H: MicroRNA-153-3p
enhances cell radiosensitivity by targeting BCL2 in human glioma.
Biol Res. 51:562018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Lv X, Fu X, Su L, Yang T and Xu P:
MiR-153 inhibits the resistance of lung cancer to gefitinib via
modulating expression of ABCE1. Cancer Biomark. 25:361–369. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grochowski CM, Loomes KM and Spinner NB:
Jagged1 (JAG1): Structure, expression, and disease associations.
Gene. 576:381–384. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou B, Zheng P, Li Z, Li H, Wang X, Shi Z
and Han Q: CircPCNXL2 sponges miR-153 to promote the proliferation
and invasion of renal cancer cells through upregulating ZEB2. Cell
Cycle. 17:2644–2654. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang H, Ge F, Xu Y, Xiao J, Zhou Z, Liu R
and Chen C: miR-153 inhibits the migration and the tube formation
of endothelial cells by blocking the paracrine of angiopoietin 1 in
breast cancer cells. Angiogenesis. 21:849–860. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Liang S and Duan X: Molecular
mechanism of miR-153 inhibiting migration, invasion and
epithelial-mesenchymal transition of breast cancer by regulating
transforming growth factor beta (TGF-β) signaling pathway. J Cell
Biochem. 120:9539–9546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shan N, Shen L, Wang J, He D and Duan C:
MiR-153 inhibits migration and invasion of human non-small-cell
lung cancer by targeting ADAM19. Biochem Biophys Res Commun.
456:385–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Z, Sun J, Bai Z, Li H, He S, Chen R
and Che X: MicroRNA-153 acts as a prognostic marker in gastric
cancer and its role in cell migration and invasion. Onco Targets
Ther. 8:357–364. 2015.PubMed/NCBI
|
|
18
|
Yang D and Zhang Q: miR-152 may function
as an early diagnostic and prognostic biomarker in patients with
cervical intraepithelial neoplasia and patients with cervical
cancer. Oncol Lett. 17:5693–5698. 2019.PubMed/NCBI
|
|
19
|
Ou ZL, Luo Z, Wei W, Liang S, Gao TL and
Lu YB: Hypoxia-induced shedding of MICA and HIF1A-mediated immune
escape of pancreatic cancer cells from NK cells: Role of
circ_0000977/miR-153 axis. RNA Biol. 16:1592–1603. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang Q, Xia J, Wang L, Wang X, Ma X, Deng
Q, Lu Y, Kumar M, Zhou Z, Li L, et al: miR-153 suppresses IDO1
expression and enhances CAR T cell immunotherapy. J Hematol Oncol.
11:582018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bai Z, Sun J, Wang X, Wang H, Pei H and
Zhang Z: MicroRNA-153 is a prognostic marker and inhibits cell
migration and invasion by targeting SNAI1 in human pancreatic
ductal adenocarcinoma. Oncol Rep. 34:595–602. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu F, Liu B, Qian J, Wu G, Li J and Ma Z:
miR-153 enhances the therapeutic effect of gemcitabine by targeting
Snail in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai).
49:520–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee J, Lee J and Kim JH: Association of
Jagged1 expression with malignancy and prognosis in human
pancreatic cancer. Cell Oncol (Dordr). 43:821–834. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao TH, Ling X, Chen C, Tang W, Hu DM and
Yin GJ: Role of miR-214-5p in the migration and invasion of
pancreatic cancer cells. Eur Rev Med Pharmacol Sci. 22:7214–7221.
2018.PubMed/NCBI
|
|
26
|
Huang SF, Yang ZL, Li DQ, Liu ZY, Wang CW,
Miao XY, Zou Q and Yuan Y: Jagged1 and DLL4 expressions in benign
and malignant pancreatic lesions and their clinicopathological
significance. Hepatobiliary Pancreat Dis Int. 15:640–646. 2016.
View Article : Google Scholar : PubMed/NCBI
|
